European Spine Journal

, Volume 15, Issue 7, pp 1035–1049 | Cite as

Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment

  • Albrecht W. Popp
  • Juerg Isenegger
  • Elizabeth M. Buergi
  • Ulrich Buergi
  • Kurt Lippuner


Glucocorticosteroid-induced osteoporosis (GIOP) is the most frequent of all secondary types of osteoporosis. The understanding of the pathophysiology of glucocorticoid (GC) induced bone loss is of crucial importance for appropriate treatment and prevention of debilitating fractures that occur predominantly in the spine. GIOP results from depressed bone formation due to lower activity and higher death rate of osteoblasts on the one hand, and from increased bone resorption due to prolonged lifespan of osteoclasts on the other. In addition, calcium/phosphate metabolism may be disturbed through GC effects on gut, kidney, parathyroid glands and gonads. Therefore, therapeutic agents aim at restoring balanced bone cell activity by directly decreasing apoptosis rate of osteoblasts (e.g., cyclical parathyroid hormone) or by increasing apoptosis rate of osteoclasts (e.g., bisphosphonates). Other therapeutical efforts aim at maintaining/restoring calcium/phosphate homeostasis: improving intestinal calcium absorption (using calcium supplementation, vitamin D and derivates) and avoiding increased urinary calcium loss (using thiazides) prevent or counteract a secondary hyperparathyroidism. Bisphosphonates, particularly the aminobisphosphonates risedronate and alendronate, have been shown to protect patients on GCs from (further) bone loss and to reduce vertebral fracture risk. Calcitonin may be of interest in situations where bisphosphonates are contraindicated or not applicable and in cases where acute pain due to vertebral fracture has to be managed. The intermittent administration of 1-34-parathormone may be an appealing treatment alternative, based on its documented anabolic effects on bone resulting from the reduction of osteoblastic apoptosis. Calcium and vitamin D should be a systematic adjunctive measure to any drug treatment for GIOP. Based on currently available evidence, fluoride, androgens, estrogens (opposed or unopposed) cannot be recommended for the prevention and treatment of GIOP. However, substitution of gonadal hormones may be indicated if GC-induced hypogonadism is present and leads to clinical symptoms. Data using the SERM raloxifene to treat or prevent GIOP are lacking, as are data using the promising bone anabolic agent strontium ranelate. Kyphoplasty performed in appropriately selected osteoporotic patients with painful vertebral fractures is a promising addition to current medical treatment.


Glucocorticosteroids Osteoporosis Pathophysiology Bisphosphonates Parathormone 


  1. 1.
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382–387CrossRefPubMedGoogle Scholar
  2. 2.
    Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211CrossRefPubMedGoogle Scholar
  3. 3.
    Adami S, Fossaluzza V, Rossini M, Bertoldo F, Gatti D, Zamberlan N, Lo Cascio V (1991) The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner 15:73–81CrossRefPubMedGoogle Scholar
  4. 4.
    Adinoff AD, Hollister JR (1983) Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265–268PubMedCrossRefGoogle Scholar
  5. 5.
    American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503Google Scholar
  6. 6.
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRefPubMedGoogle Scholar
  7. 7.
    Bean JF, Vora A, Frontera WR (2004) Benefits of exercise for community-dwelling older adults. Arch Phys Med Rehabil 85:S31–S42CrossRefPubMedGoogle Scholar
  8. 8.
    Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O’Brien CA, Manolagas SC, Jilka RL (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259–50272CrossRefPubMedGoogle Scholar
  9. 9.
    Bijlsma JW, Raymakers JA, Mosch C, Hoekstra A, Derksen RH, Baart de la Faille H, Duursma SA (1988) Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol 6:113–119PubMedGoogle Scholar
  10. 10.
    Borer KT (2005) Physical activity in the prevention and amelioration of osteoporosis in women: interaction of mechanical, hormonal and dietary factors. Sports Med 35:779–830CrossRefPubMedGoogle Scholar
  11. 11.
    Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP (1997) Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 61:266–271CrossRefPubMedGoogle Scholar
  12. 12.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16:104–112PubMedGoogle Scholar
  13. 13.
    Braun JJ, Birkenhager-Frenkel DH, Rietveld AH, Juttmann JR, Visser TJ, Birkenhager JC (1983) Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study. Clin Endocrinol (Oxf) 19:265–273Google Scholar
  14. 14.
    Buckley LM, Hillner BE (2003) A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J Rheumatol 30:132–138PubMedGoogle Scholar
  15. 15.
    Buckley LM, Marquez M, Hudson JO, Downs RW, Vacek P, Small RE, Poses R (1998) Variations in physicians’ judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol 25:2195–2202PubMedGoogle Scholar
  16. 16.
    Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM (2004) Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 59:761–768CrossRefPubMedGoogle Scholar
  17. 17.
    Caniggia A, Nuti R, Lore F, Vattimo A (1981) Pathophysiology of the adverse effects of glucoactive corticosteroids on calcium metabolism in man. J Steroid Biochem 15:153–161CrossRefPubMedGoogle Scholar
  18. 18.
    Chyun YS, Kream BE, Raisz LG (1984) Cortisol decreases bone formation by inhibiting periosteal cell proliferation. Endocrinology 114:477–480PubMedCrossRefGoogle Scholar
  19. 19.
    Cohen D, Adachi JD (2004) The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol 88:337–349CrossRefPubMedGoogle Scholar
  20. 20.
    Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318CrossRefPubMedGoogle Scholar
  21. 21.
    Compston J (2003) Glucocorticoid-induced osteoporosis. Horm Res 60(Suppl 3):77–79CrossRefPubMedGoogle Scholar
  22. 22.
    Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM (2002) Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17:979–986PubMedGoogle Scholar
  23. 23.
    Cooper MS, Blumsohn A, Goddard PE, Bartlett WA, Shackleton CH, Eastell R, Hewison M, Stewart PM (2003) 11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab 88:3874–3877CrossRefPubMedGoogle Scholar
  24. 24.
    Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, Tugwell P, Wells G (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev CD001983Google Scholar
  25. 25.
    Crilly R, Cawood M, Marshall DH, Nordin BE (1978) Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women. J R Soc Med 71:733–736PubMedGoogle Scholar
  26. 26.
    Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339:733–738CrossRefPubMedGoogle Scholar
  27. 27.
    Delany AM, Durant D, Canalis E (2001) Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 15:1781–1789CrossRefPubMedGoogle Scholar
  28. 28.
    de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589–602CrossRefPubMedGoogle Scholar
  29. 29.
    Diamond T, McGuigan L, Barbagallo S, Bryant C (1995) Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 98:459–463CrossRefPubMedGoogle Scholar
  30. 30.
    Diamond TH, Champion B, Clark WA (2003) Management of acute osteoporotic vertebral fractures: a nonrandomized trial comparing percutaneous vertebroplasty with conservative therapy. Am J Med 114:257–265CrossRefPubMedGoogle Scholar
  31. 31.
    Donovan MA, Khandji AG, Siris E (2004) Multiple adjacent vertebral fractures after kyphoplasty in a patient with steroid-induced osteoporosis. J Bone Miner Res 19:712–713PubMedGoogle Scholar
  32. 32.
    Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ (1998) A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244:271–292CrossRefPubMedGoogle Scholar
  33. 33.
    Fentiman IS, Saad Z, Caleffi M, Chaudary MA, Fogelman I (1992) Tamoxifen protects against steroid-induced bone loss. Eur J Cancer 28:684–685CrossRefPubMedGoogle Scholar
  34. 34.
    Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marcolongo R (2003) Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone 33:575–581CrossRefPubMedGoogle Scholar
  35. 35.
    Gennari C (1993) Differential effect of glucocorticoids on calcium absorption and bone mass. Br J Rheumatol 32(Suppl 2):11–14PubMedGoogle Scholar
  36. 36.
    Gennari C, Civitelli R (1986) Glucocorticoid-induced osteoporosis. Clin Rheum Dis 12:637–654PubMedGoogle Scholar
  37. 37.
    Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, Nijs J, Raus J (1998) Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann Rheum Dis 57:724–727PubMedGoogle Scholar
  38. 38.
    Geusens PP, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP, Bijlsma JW (2004) Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 63:324–325CrossRefPubMedGoogle Scholar
  39. 39.
    Glassman SD, Alegre GM (2003) Adult spinal deformity in the osteoporotic spine: options and pitfalls. Instr Course Lect 52:579–588PubMedGoogle Scholar
  40. 40.
    Gluck OS, Murphy WA, Hahn TJ, Hahn B (1981) Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 24:892–898PubMedGoogle Scholar
  41. 41.
    Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M, Gennari C (1997) Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 61:382–385CrossRefPubMedGoogle Scholar
  42. 42.
    Grecu EO, Weinshelbaum A, Simmons R (1990) Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 46:294–299PubMedGoogle Scholar
  43. 43.
    Greenwald M, Brandli D, Spector S, Silverman S, Golde G (1992) Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride. Osteoporos Int 2:303–304CrossRefPubMedGoogle Scholar
  44. 44.
    Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 11:727–738CrossRefPubMedGoogle Scholar
  45. 45.
    Hahn TJ, Boisseau VC, Avioli LV (1974) Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metab 39:274–282PubMedGoogle Scholar
  46. 46.
    Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH (1979) Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest 64:655–665PubMedGoogle Scholar
  47. 47.
    Hahn TJ, Halstead LR, Baran DT (1981) Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 52:111–115PubMedGoogle Scholar
  48. 48.
    Hall GM, Spector TD, Griffin AJ, Jawad AS, Hall ML, Doyle DV (1993) The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 36:1510–1516PubMedGoogle Scholar
  49. 49.
    Hall GM, Daniels M, Doyle DV, Spector TD (1994) Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37:1499–1505PubMedGoogle Scholar
  50. 50.
    Harrop JS, Prpa B, Reinhardt MK, Lieberman I (2004) Primary and secondary osteoporosis’ incidence of subsequent vertebral compression fractures after kyphoplasty. Spine 29:2120–2125CrossRefPubMedGoogle Scholar
  51. 51.
    Herrala J, Puolijoki H, Liippo K, Raitio M, Impivaara O, Tala E, Nieminen MM (1998) Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone 22:577–582CrossRefPubMedGoogle Scholar
  52. 52.
    Hock JM, Gera I (1992) Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65–72PubMedGoogle Scholar
  53. 53.
    Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE (2002) Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 166:1563–1566CrossRefPubMedGoogle Scholar
  54. 54.
    Ip M, Lam K, Yam L, Kung A, Ng M (1994) Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 105:1722–1727PubMedGoogle Scholar
  55. 55.
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439–446PubMedGoogle Scholar
  56. 56.
    Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G (2002) Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev CD003537Google Scholar
  57. 57.
    Kaplan RS, Sinaki M, Hameister MD (1996) Effect of back supports on back strength in patients with osteoporosis: a pilot study. Mayo Clin Proc 71:235–241PubMedGoogle Scholar
  58. 58.
    Kasperk C, Hillmeier J, Noldge G, Grafe IA, Dafonseca K, Raupp D, Bardenheuer H, Libicher M, Liegibel UM, Sommer U, Hilscher U, Pyerin W, Vetter M, Meinzer HP, Meeder PJ, Taylor RS, Nawroth P (2005) Treatment of painful vertebral fractures by kyphoplasty in patients with primary osteoporosis: a prospective nonrandomized controlled study. J Bone Miner Res 20:604–612PubMedGoogle Scholar
  59. 59.
    Kerschan K, Alacamlioglu Y, Kollmitzer J, Wober C, Kaider A, Hartard M, Ghanem AH, Preisinger E (1998) Functional impact of unvarying exercise program in women after menopause. Am J Phys Med Rehabil 77:326–332CrossRefPubMedGoogle Scholar
  60. 60.
    Kerschan-Shindl K, Uher E, Kainberger F, Kaider A, Ghanem AH, Preisinger E (2000) Long-term home exercise program: effect in women at high risk of fracture. Arch Phys Med Rehabil 81:319–323CrossRefPubMedGoogle Scholar
  61. 61.
    Krogsgaard MR, Thamsborg G, Lund B (1996) Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Ann Rheum Dis 55:143–146PubMedGoogle Scholar
  62. 62.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633PubMedGoogle Scholar
  63. 63.
    Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD (2000) Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434–442CrossRefPubMedGoogle Scholar
  64. 64.
    Lems WF, Jacobs WG, Bijlsma JW, Croone A, Haanen HC, Houben HH, Gerrits MI, van Rijn HJ (1997) Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int 7:575–582PubMedGoogle Scholar
  65. 65.
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–555CrossRefPubMedGoogle Scholar
  66. 66.
    Lippuner K, Haller B, Casez JP, Montandon A, Jaeger P (1996) Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study. Miner Electrolyte Metab 22:207–213PubMedGoogle Scholar
  67. 67.
    Lippuner K, Casez JP, Horber FF, Jaeger P (1998) Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab 83:3795–3802CrossRefPubMedGoogle Scholar
  68. 68.
    Lipworth BJ (1999) Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159:941–955CrossRefPubMedGoogle Scholar
  69. 69.
    LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, DellaRocca C (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39–51CrossRefPubMedGoogle Scholar
  70. 70.
    LoCascio V, Ballanti P, Milani S, Bertoldo F, LoCascio C, Zanolin EM, Bonucci E (1998) A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort. Calcif Tissue Int 62:199–204CrossRefPubMedGoogle Scholar
  71. 71.
    Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J (1991) Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 46:803–806PubMedGoogle Scholar
  72. 72.
    Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352–364PubMedGoogle Scholar
  73. 73.
    Lukert BP, Johnson BE, Robinson RG (1992) Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 7:1063–1069PubMedCrossRefGoogle Scholar
  74. 74.
    Lyles KW, Gold DT, Shipp KM, Pieper CF, Martinez S, Mulhausen PL (1993) Association of osteoporotic vertebral compression fractures with impaired functional status. Am J Med 94:595–601CrossRefPubMedGoogle Scholar
  75. 75.
    MacAdams MR, White RH, Chipps BE (1986) Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 104:648–651PubMedGoogle Scholar
  76. 76.
    Manolagas SC (1999) Cell number versus cell vigor—what really matters to a regenerating skeleton? Endocrinology 140:4377–4381CrossRefPubMedGoogle Scholar
  77. 77.
    Manolagas SC, Weinstein RS (1999) New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14:1061–1066PubMedGoogle Scholar
  78. 78.
    Mathis JM, Petri M, Naff N (1998) Percutaneous vertebroplasty treatment of steroid-induced osteoporotic compression fractures. Arthritis Rheum 41:171–175CrossRefPubMedGoogle Scholar
  79. 79.
    McCarthy TL, Ji C, Chen Y, Kim K, Centrella M (2000) Time- and dose-related interactions between glucocorticoid and cyclic adenosine 3′,5′-monophosphate on CCAAT/enhancer-binding protein-dependent insulin-like growth factor I expression by osteoblasts. Endocrinology 141:127–137CrossRefPubMedGoogle Scholar
  80. 80.
    McKiernan F, Faciszewski T, Jensen R (2004) Quality of life following vertebroplasty. J Bone Joint Surg Am 86-A:2600–2606PubMedGoogle Scholar
  81. 81.
    Messina OD, Barreira JC, Zanchetta JR, Maldonado-Cocco JA, Bogado CE, Sebastian ON, Flores D, Riopedre AM, Redondo G, Lazaro A (1992) Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol 19:1520–1526PubMedGoogle Scholar
  82. 82.
    Meys E, Terreaux-Duvert F, Beaume-Six T, Dureau G, Meunier PJ (1993) Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate. Osteoporos Int 3:322–329CrossRefPubMedGoogle Scholar
  83. 83.
    Michel BA, Bloch DA, Fries JF (1991) Predictors of fractures in early rheumatoid arthritis. J Rheumatol 18:804–808PubMedGoogle Scholar
  84. 84.
    Morrison D, Ali NJ, Routledge PA, Capewell S (1992) Bone turnover during short course prednisolone treatment in patients with chronic obstructive airways disease. Thorax 47:418–420PubMedCrossRefGoogle Scholar
  85. 85.
    Mulder H, Struys A (1994) Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 33:348–350PubMedGoogle Scholar
  86. 86.
    Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD (2004) Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 31:550–556PubMedGoogle Scholar
  87. 87.
    Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109CrossRefPubMedGoogle Scholar
  88. 88.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMedGoogle Scholar
  89. 89.
    O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841CrossRefPubMedGoogle Scholar
  90. 90.
    Pereira RM, Delany AM, Canalis E (2001) Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 28:484–490CrossRefPubMedGoogle Scholar
  91. 91.
    Pereira RC, Delany AM, Canalis E (2002) Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30:685–691CrossRefPubMedGoogle Scholar
  92. 92.
    Pereira RM, Delany AM, Durant D, Canalis E (2002) Cortisol regulates the expression of Notch in osteoblasts. J Cell Biochem 85:252–258CrossRefPubMedGoogle Scholar
  93. 93.
    Pfeifer M, Sinaki M, Geusens P, Boonen S, Preisinger E, Minne HW (2004) Musculoskeletal rehabilitation in osteoporosis: a review. J Bone Miner Res 19:1208–1214PubMedGoogle Scholar
  94. 94.
    Phillips EM, Bodenheimer CF, Roig RL, Cifu DX (2004) Geriatric rehabilitation. 4. Physical medicine and rehabilitation interventions for common age-related disorders and geriatric syndromes. Arch Phys Med Rehabil 85:S18–S22CrossRefPubMedGoogle Scholar
  95. 95.
    Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C (1998) A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax 53:351–356PubMedGoogle Scholar
  96. 96.
    Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363–1374PubMedGoogle Scholar
  97. 97.
    Pocock NA, Eisman JA, Dunstan CR, Evans RA, Thomas DH, Huq NL (1987) Recovery from steroid-induced osteoporosis. Ann Intern Med 107:319–323PubMedGoogle Scholar
  98. 98.
    Priftis K, Everard ML, Milner AD (1991) Unexpected side-effects of inhaled steroids: a case report. Eur J Pediatr 150:448–449CrossRefPubMedGoogle Scholar
  99. 99.
    Prior JC (1990) Progesterone as a bone-trophic hormone. Endocr Rev 11:386–398PubMedGoogle Scholar
  100. 100.
    Prior JC, Barr SI, Chow R, Faulkner RA (1996) Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis. CMAJ 155:940–944PubMedGoogle Scholar
  101. 101.
    Reginster JY, de Froidmont C, Lecart MP, Sarlet N, Defraigne JO (1999) Alphacalcidol in prevention of glucocorticoid-induced osteoporosis. Calcif Tissue Int 65:328–331CrossRefPubMedGoogle Scholar
  102. 102.
    Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ, Nielsen K (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9:75–81CrossRefPubMedGoogle Scholar
  103. 103.
    Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE (2003) Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 14:77–81CrossRefPubMedGoogle Scholar
  104. 104.
    Reid IR (1989) Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol (Oxf) 30:83–103Google Scholar
  105. 105.
    Reid IR, Heap SW (1990) Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 150:2545–2548CrossRefPubMedGoogle Scholar
  106. 106.
    Reid IR, Ibbertson HK (1987) Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. Horm Res 27:200–204PubMedCrossRefGoogle Scholar
  107. 107.
    Reid IR, King AR, Alexander CJ, Ibbertson HK (1988) Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:143–146CrossRefPubMedGoogle Scholar
  108. 108.
    Reid IR, Wattie DJ, Evans MC, Stapleton JP (1996) Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156:1173–1177CrossRefPubMedGoogle Scholar
  109. 109.
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013PubMedGoogle Scholar
  110. 110.
    Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242–247CrossRefPubMedGoogle Scholar
  111. 111.
    Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2001) Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med 250:144–153CrossRefPubMedGoogle Scholar
  112. 112.
    Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301–310CrossRefPubMedGoogle Scholar
  113. 113.
    Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY (2005) Vitamin D analogs versus native vitamin d in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 76(3):176–186CrossRefPubMedGoogle Scholar
  114. 114.
    Rickers H, Deding A, Christiansen C, Rodbro P, Naestoft J (1982) Corticosteroid-induced osteopenia and vitamin D metabolism. Effect of vitamin D2, calcium phosphate and sodium fluoride administration. Clin Endocrinol (Oxf) 16:409–415Google Scholar
  115. 115.
    Ringe JD (1989) Glucocorticoid-induced osteoporosis. Clin Rheumatol 8(Suppl 2):109–115CrossRefPubMedGoogle Scholar
  116. 116.
    Ringe JD, Welzel D (1987) Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 33:35–39PubMedGoogle Scholar
  117. 117.
    Rizzato G, Montemurro L (1993) Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J 6:116–119PubMedGoogle Scholar
  118. 118.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMedGoogle Scholar
  119. 119.
    Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouilles JM, Horlait S, Cortet B (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 83:1128–1133CrossRefPubMedGoogle Scholar
  120. 120.
    Ruegsegger P, Medici TC, Anliker M (1983) Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 25:615–620CrossRefPubMedGoogle Scholar
  121. 121.
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299CrossRefPubMedGoogle Scholar
  122. 122.
    Sakakura M, Takebe K, Nakagawa S (1975) Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 40:774–779PubMedGoogle Scholar
  123. 123.
    Sambrook P, Nguyen T (1992) Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Br J Rheumatol 31:573–574PubMedGoogle Scholar
  124. 124.
    Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG (1989) Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 48:535–538PubMedGoogle Scholar
  125. 125.
    Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752CrossRefPubMedGoogle Scholar
  126. 126.
    Sambrook PN, Kelly PJ, Keogh AM, Macdonald P, Spratt P, Freund J, Eisman JA (1994) Bone loss after heart transplantation: a prospective study; discussion 121. J Heart Lung Transplant 13:116–120PubMedGoogle Scholar
  127. 127.
    Schneider HP (2003) Androgens and antiandrogens. Ann NY Acad Sci 997:292–306CrossRefPubMedGoogle Scholar
  128. 128.
    Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL (1982) Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest 69:1302–1309PubMedGoogle Scholar
  129. 129.
    Sinaki M (2003) Nonpharmacologic interventions. Exercise, fall prevention, and role of physical medicine. Clin Geriatr Med 19:337–359CrossRefPubMedGoogle Scholar
  130. 130.
    Snyder BD, Zaltz I, Breitenbach MA, Kido TH, Myers ER, Emans JB (1995) Does bracing affect bone density in adolescent scoliosis? Spine 20:1554–1560PubMedCrossRefGoogle Scholar
  131. 131.
    Snyder BD, Katz DA, Myers ER, Breitenbach MA, Emans JB (2005) Bone density accumulation is not affected by brace treatment of idiopathic scoliosis in adolescent girls. J Pediatr Orthop 25:423–428CrossRefPubMedGoogle Scholar
  132. 132.
    Stellon AJ, Webb A, Compston JE (1988) Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. Gut 29:378–384PubMedGoogle Scholar
  133. 133.
    Stevens JA, Olson S (2000) Reducing falls and resulting hip fractures among older women. MMWR Recomm Rep 49:3–12PubMedGoogle Scholar
  134. 134.
    Suzuki Y, Ichikawa Y, Saito E, Homma M (1983) Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32:151–156CrossRefPubMedGoogle Scholar
  135. 135.
    Tenenbaum HC, Kamalia N, Sukhu B, Limeback H, McCulloch CA (1995) Probing glucocorticoid-dependent osteogenesis in rat and chick cells in vitro by specific blockade of osteoblastic differentiation with progesterone and RU38486. Anat Rec 242:200–210CrossRefPubMedGoogle Scholar
  136. 136.
    Uzawa T, Hori M, Ejiri S, Ozawa H (1995) Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1–34) on rat bone. Bone 16:477–484PubMedGoogle Scholar
  137. 137.
    van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedGoogle Scholar
  138. 138.
    van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389CrossRefGoogle Scholar
  139. 139.
    van Staa TP, Leufkens HG, Cooper C (2001) Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 16:581–588PubMedGoogle Scholar
  140. 140.
    van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRefPubMedGoogle Scholar
  141. 141.
    van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229PubMedGoogle Scholar
  142. 142.
    van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98:191–198CrossRefPubMedGoogle Scholar
  143. 143.
    Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285CrossRefPubMedGoogle Scholar
  144. 144.
    Weinstein RS (2001) Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2:65–73CrossRefPubMedGoogle Scholar
  145. 145.
    Weinstein RS, Manolagas SC (2000) Apoptosis and osteoporosis. Am J Med 108:153–164CrossRefPubMedGoogle Scholar
  146. 146.
    Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274–282PubMedCrossRefGoogle Scholar
  147. 147.
    Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC (2002) Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109:1041–1048CrossRefPubMedGoogle Scholar
  148. 148.
    Wolinsky-Friedland M (1995) Drug-induced metabolic bone disease. Endocrinol Metab Clin North Am 24:395–420PubMedGoogle Scholar
  149. 149.
    Wong CA, Walsh LJ, Smith CJ, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE (2000) Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 355:1399–1403CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Albrecht W. Popp
    • 1
  • Juerg Isenegger
    • 2
  • Elizabeth M. Buergi
    • 2
  • Ulrich Buergi
    • 2
  • Kurt Lippuner
    • 1
  1. 1.Osteoporosis PoliclinicUniversity Hospital of BerneBerne Switzerland
  2. 2.Department of Internal MedicineUniversity Hospital of BerneBerne Switzerland

Personalised recommendations